0001213900-22-027887.txt : 20220518 0001213900-22-027887.hdr.sgml : 20220518 20220518133453 ACCESSION NUMBER: 0001213900-22-027887 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220512 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220518 DATE AS OF CHANGE: 20220518 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39685 FILM NUMBER: 22938059 BUSINESS ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 8-K 1 ea160171-8k_inmedphar.htm CURRENT REPORT
0001728328 false A1 0001728328 2022-05-12 2022-05-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

 

 

Date of Report (Date of earliest event reported): May 12, 2022

 

 

 

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

 

 

 

British Columbia   001-39685   98-1428279

(State or Other Jurisdiction

of Incorporation)

  

(Commission File Number)

  

(IRS Employer

Identification No.)

 

InMed Pharmaceuticals Inc.

Suite 310 - 815 W. Hastings Street, 

Vancouver, B.C. 

Canada

   V6C 1B4
(Address of Principal Executive Offices)   (Zip Code)

 

Company’s telephone number, including area code: (604) 669-7207

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading Symbol(s)

   Name of each exchange
on which registered
Common Shares, no par value   INM   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(d)On May 12, 2022, the Board appointed Bryan Baldasare as a director of the Board and concurrently increased the size of the Board to six members, effective as of May 12, 2022. Mr. Baldasare is a well-rounded biotech executive with a wealth of experience in finance and accounting, financial planning and analysis, treasury management, commercial operations and mergers and acquisitions. Mr. Baldasare spent over 20 years at Meridian Bioscience, most recently as Chief Financial Officer where during his tenure, it grew its revenues by over 500%, developed and launched dozens of new products, and expanded into a diversified global business with 15 sites in 10 countries. Mr. Baldasare is currently the CFO at Hilltop Companies, a leading supplier to the construction industry. Prior to Meridian, Mr. Baldasare spent over 10 years in public accounting at Arthur Andersen LLP.

 

Mr. Baldasare’s term as a member of the Board will expire at the Annual General Meeting to be held in 2023. Mr. Baldasare will serve on the Audit Committee and the Governance and Nomination Committee. There are no arrangements nor understandings with Mr. Baldasare pursuant to which he was selected as a director of the Company, and there is no family relationship between Mr. Baldasare and any of the Company’s other directors or executive officers. Mr. Baldasare will be entitled to receive the standard compensation provided to Directors of an annual retainer of $35,000 and for committee participation, directors are eligible to receive up to an additional $15,000 per year assuming a minimum of two committee memberships.

 

  In connection with his appointment to the Board, Mr. Baldasare executed the Company’s standard form of indemnification agreement for directors.

 

  On May 13, 2022, the Company issued a press release which included information regarding Mr. Baldasare’s appointment to the Board.

 

Item 7.01 Regulation FD Disclosure.

 

On May 13, 2022, the Company announced financial results for the third quarter of fiscal year 2022 which ended March 31, 2021. A copy of the press release issued is filed as Exhibit 99.1 to, and is incorporated by reference into, this Item 7.01.

 

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

The following exhibits shall be deemed to be furnished, and not filed:

 

Exhibit No.   Description
99.1   Press release, dated May 13, 2022
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INMED PHARMACEUTICALS INC.
     
Date: May 17, 2022 By: /s/ Brenda Edwards
    Brenda Edwards
    Interim Chief Financial Officer

 

 

2

 
 EX-99.1 2 ea160171ex99-1_inmedphar.htm PRESS RELEASE, DATED MAY 13, 2022

Exhibit 99.1

 

NASDAQ: INM

 

Suite 310-815 W. Hastings St.

Vancouver, BC, Canada V6C 1B4

Tel: +1.604.669.7207

Email: info@inmedpharma.com

www.inmedpharma.com

 

InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update

 

●Expands rare cannabinoid portfolio with the addition of CBT and CBDV
●Strengthens IP with publication of a patent application for novel cannabinoid analogs
●Advances the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative diseases

 

Vancouver, BC and South San Francisco, CA – May 13, 2022 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced financial results for the third quarter of the fiscal year 2022 which ended March 31, 2022.

 

“The third quarter of fiscal 2022 saw noticeable advancements across all of our programs, including commencing sales of the rare cannabinoids CBDV and CBT as raw ingredients for the health and wellness industry,” says Eric A. Adams, InMed President & CEO. “For the remainder of fiscal 2022, we will remain focused on driving our commercial operations by expanding our product portfolio, increasing sales of our existing and new rare cannabinoids, exploring new distribution channels and optimizing our product development and supply chain strategy. We continue to grow revenues and have established a solid platform upon which to build as we commercialize additional high value products. We continue to focus on enhancing our sales and marketing efforts to support increasing demand.”

 

Business Update

 

Commercial Activities

In January 2022, InMed announced that it launched B2B sales of cannabicitran (“CBT”) to wholesalers, suppliers and end-product manufacturers in the health and wellness sector via its wholly-owned subsidiary, BayMedica LLC. Subsequent to the quarter end, the Company also commenced sales of the rare cannabinoid cannabidivarin (“CBDV”) in April, marking the third product in the Company’s rare cannabinoid commercial portfolio, which also includes cannabichromene (“CBC”). BayMedica has also begun commercial scale production of its delta-9 dominant tetrahydrocannabivarin (“THCV”) in anticipation of commencing B2B sales. CBDV and THCV are highly anticipated, non-intoxicating rare cannabinoids for which is there is growing interest.

 

 

 

 

Continuing to build out a robust product portfolio is a strategic priority and the Company currently has several additional high-value rare cannabinoids in various stages of development and commercial manufacturing scale-up.

 

By establishing a reliable supply of these rare cannabinoids at commercial scale, innovative product manufacturers and consumer brands now have the ability to deliver improved and differentiated products via product line extensions and formulations designed to increase the performance of their products.

 

In addition to sales of rare cannabinoids as raw ingredients, the Company is also evaluating potential partners and co-development collaborations for novel product development. Formulated cannabinoid products in different delivery forms can help to expand product development options for manufacturers of health and wellness products.

 

Also following the quarter’s end, BayMedica announced they will be supplying the rare cannabinoid THCV for incorporation into Trokie’s proprietary product formulation. This will then be evaluated in Radicle Science’s “Radicle Energy” study on energy, focus/attention, appetite and weight/body mass index (“BMI”). The study is being conducted to provide valuable third party validation to the use case of THCV. Advancing the scientific research and education of rare cannabinoids is a key part of InMed’s commitment to building the framework that supports the Company’s long-term commercial strategy.

 

To support our commercial efforts, in February the Company appointed seasoned business executive, Jerry P. Griffin, as VP of Sales and Marketing. Mr. Griffin has a wealth of experience across various markets and with numerous cannabinoid products, and a proven track record as a seasoned sales executive. He has held several senior positions at both privately and publicly held companies including Fortune 500 companies as a strong strategic leader and has the requisite experience to oversee the commercial ramp-up of B2B sales of rare cannabinoids products to the consumer health and wellness market.

 

Pharmaceutical Development Programs

 

INM-755 for the treatment of Epidermolysis Bullosa (“EB”)

 

Enrollment and patient treatment of the Company’s Phase 2 clinical trial, 755-201-EB, of INM-755 (cannabinol) cream in the treatment of EB, commenced in December of 2021 and is expected to complete during the calendar year 2022. An update on the progress of the EB program is expected in the coming weeks.

 

The 755-201-EB study is designed to enroll up to 20 patients. InMed is evaluating the safety of INM-755 (cannabinol) cream and its preliminary efficacy in treating symptoms and wound healing over a 28-day treatment period. This study marks the first time cannabinol (“CBN”) has advanced to a Phase 2 clinical trial to be investigated as a therapeutic option to treat a disease.

 

2

 

 

INM-088 for the treatment of glaucoma

 

The Company recently completed a pre-Investigational New Drug (“pIND”) application discussion with the U.S. Food and Drug Administration (“FDA”) regarding manufacturing, preclinical studies and early clinical development plans for INM-088, a cannabinol (“CBN”) formulation in development for glaucoma. The Company has gained alignment with FDA on the design of the initial Phase 1-2 clinical trial to gather preliminary data on the safety and efficacy of INM-088 treatment. The FDA has provided guidance for the development program based on a summary of the available preclinical data, clinical safety data for CBN from the INM-755 program, study designs for additional IND-enabling preclinical studies, and Chemistry Manufacturing and Controls (“CMC”) information. Management expects to file regulatory applications in the first half of the calendar year 2023, to initiate a human clinical trial.

 

The Company continues to advance its pre-clinical research on CBN as a treatment for glaucoma. As referenced in a recent international journal, InMed’s research demonstrates that CBN was effective at providing neuroprotection to the retinal ganglion cells and reducing intraocular pressure in glaucoma models and outperforming several other naturally occurring cannabinoids.

 

New Cannabinoid analogs

In April 2022, the Company announced the publication of a patent application in North America for several cannabinoid analogs. This patent application has broad claims directed to their molecular structure, uses and methods of manufacturing. The patent application covers technology that allows for the creation of libraries of new chemical entities (“NCEs”), which the Company will screen in several in vitro and in vivo models to select therapeutic candidates for advancement. Unlike natural cannabinoids isolated from the plant which are not patentable, these cannabinoid analogs are patentable and may create potential value for the Company. 

 

In addition, the Company also initiated a research collaboration agreement with the Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila (Italy) in the laboratory of Dr. Mauro Maccarrone. Dr. Maccarrone’s lab will be screening the Company’s novel cannabinoid analogs to investigate pharmacological properties and potential therapeutic uses.

 

Corporate

 

Today the Company would like to announce that Mr. Bryan Baldasare has joined the Board of Directors effective immediately.

 

Mr. Baldasare is a well-rounded biotech executive with wealth of experience in finance and accounting, financial planning and analysis, treasury management, commercial operations and mergers and acquisitions. Mr. Baldasare spent over 20 years at Meridian Bioscience, most recently as Chief Financial Officer where during his tenure, grew its revenues by over 500%, developed and launched dozens of new products, expanded into a diversified global business with 15 sites in 10 countries. Mr. Baldasare is currently the CFO at Hilltop Companies, a leading supplier to the construction industry. Prior to Meridian, Mr. Baldasare spent over 10 years in public accounting at Arthur Andersen LLP. Mr. Baldasare has a Bachelor’s degree in Business Administration from the University of Cincinnati.

 

As noted earlier, in February, the Company also appointed Jerry Griffin as VP of Sales and Marketing.

 

3

 

 

Financial and Operational Highlights:

 

For the 9 months ended March 31, 2022, the Company recorded a net loss of $10.7 million, or $0.81 per share, compared with a net loss of $6.9 million, or $1.11 per share, for the nine months ended March 31, 2021.

Research and development and patents expenses increased by $2.2 million for the nine months ended March 31, 2022 compared to the nine months ended March 31, 2021. The increase in research and development and patents expenses was primarily due to increased activities related to the INM-755 clinical trial and the addition of $0.9 million in our BayMedica segment following the acquisition date.

 

The Company incurred general and administrative expenses of $5.1 million for the nine months ended March 31, 2022 compared with $2.9 million for the nine months ended March 31, 2021. The increase results primarily from the inclusion of BayMedica operating results following the acquisition date and combination of changes including legal fees and investor relation expenses, personnel expenses, substantially higher insurance fees resulting from our listing on the Nasdaq Capital Market. In addition, acquisition-related expenses, which were comprised of regulatory, financial advisory and legal fees, totaled $0.2 million for the nine months ended March 31, 2022 and were included in general and administrative expenses in our InMed segment.

 

At March 31, 2022, the Company’s cash, cash equivalents and short-term investments were $5.9 million, which compares to $7.4 million at June 30, 2021. The change in cash, cash equivalents and short-term investments during the nine months to March 31, 2022, was primarily the result of the July 2, 2021 private placement partially offset by cash outflows from operating activities.

 

At March 31, 2022, the Company’s total issued and outstanding shares were 14,283,848. During the three and nine months ending March 31, 2022, the weighted average number of common shares was 14,151,544 and 13,326,754, which is used for the calculation of loss per share for the respective interim periods.

 

BayMedica Revenue

 

Results subsequent the acquisition of BayMedica in October 2021, are net sales of $0.6 million for the six months ended March 31, 2022 for cannabinoid ingredient sales to wholesalers and product manufacturers in the health and wellness sector. As the nine months ended March 31, 2021 pre-dated the acquisition of BayMedica there are no comparable revenues in the 2021 period. Accordingly, we realized cost of goods sold of $0.3 million for the nine months ended March 31, 2022, with no comparable expenses in 2021, resulting in a gross profit of $0.3 million for the period.

 

Reported sales were impacted this quarter by a delay in the product launches of two new rare cannabinoids, CBDV and THCV. CBDV was launched subsequent to quarter end and the commercial launch of THCV is planned shortly. With the commercialization of these products and additional launches being planned, the Company anticipates revenue growth in the coming quarters.

 

4

 

 

Table 1: Condensed Consolidated Interim Balance Sheets (unaudited):

 

InMed Pharmaceuticals Inc.

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (unaudited)

As at March 31, 2022 and June 30, 2021

Expressed in U.S. Dollars    

 

   March 31,   June 30, 
   2022   2021 
         
ASSETS  $   $ 
Current        
Cash and cash equivalents   5,898,313    7,363,126 
Short-term investments   46,098    46,462 
Accounts receivable   70,554    11,919 
Inventories   1,420,382    - 
Prepaids and other assets   1,311,539    956,762 
Total current assets   8,746,886    8,378,269 
           
Non-Current          
Property and equipment, net   1,002,846    326,595 
Intangible assets, net   2,355,401    1,061,697 
In-process research and development   1,249,000    - 
Goodwill   2,023,039    - 
Other assets   108,625    14,655 
Total Assets   15,485,797    9,781,216 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current          
Accounts payable and accrued liabilities   2,866,927    2,134,878 
Short-term debt   29,312    - 
Current portion of lease obligations   399,904    80,483 
Deferred revenue   8,902    - 
Acquisition consideration payable   800,457    - 
Total current liabilities   4,105,502    2,215,361 
           
Non-current          
Lease obligations   493,562    189,288 
Total Liabilities   4,599,064    2,404,649 
           
Shareholders’ Equity          
Common shares, no par value, unlimited authorized shares:          
14,283,848 (June 30, 2021 - 8,050,707) issued and outstanding   69,825,331    60,587,417 
Additional paid-in capital   26,515,397    21,513,051 
Accumulated deficit   (85,582,564)   (74,852,470)
Accumulated other comprehensive income   128,569    128,569 
Total Shareholders’ Equity   10,886,733    7,376,567 
Total Liabilities and Shareholders’ Equity   15,485,797    9,781,216 

 

5

 

 

Table 2: Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (unaudited):

 

InMed Pharmaceuticals Inc.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited)

For the three and nine months ended March 31, 2022 and 2021

Expressed in U.S. Dollars      

 

   Three Months Ended   Nine Months Ended 
   March 31   March 31 
   2022   2021   2022   2021 
   $   $   $   $ 
                 
Sales   309,585    -    574,677    - 
Cost of sales   127,308    -    280,845    - 
Gross profit   182,277    -    293,832    - 
                     
Operating Expenses                    
Research and development and patents   1,753,545    1,772,593    5,781,867    3,621,697 
General and administrative   1,915,017    1,333,725    5,124,670    2,918,067 
Amortization and depreciation   53,340    27,421    131,669    92,218 
Total operating expenses   3,721,902    3,133,739    11,038,206    6,631,982 
                     
Other Income (Expense)                    
Interest and other income   30,964    3,797    62,389    11,192 
Finance expense   -    -    -    (360,350)
Unrealized gain on derivative warrants liability   -    -    -    242,628 
Foreign exchange gain (loss)   32,996    28,467    (48,109)   (205,824)
Net loss for the period   (3,475,665)   (3,101,475)   (10,730,094)   (6,944,336)
                     
Other Comprehensive Loss                    
Foreign currency translation gain   -    -    -    430,443 
Total comprehensive loss for the period   (3,475,665)   (3,101,475)   (10,730,094)   (6,513,893)
                     
Net loss per share for the period                    
Basic and diluted   (0.25)   (0.41)   (0.81)   (1.11)
Weighted average outstanding common shares                    
Basic and diluted   14,151,544    7,549,040    13,326,754    6,277,824 

 

6

 

 

Table 3: Condensed Consolidated Interim Statements of Cash Flows (unaudited):

 

InMed Pharmaceuticals Inc.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (unaudited)

For the nine months ended March 31, 2022 and 2021

Expressed in U.S. Dollars    

 

   2022   2021 
         
Cash provided by (used in):  $   $ 
         
Operating Activities        
Net loss for the period   (10,730,094)   (6,944,336)
Items not requiring cash:          
Amortization and depreciation   131,669    92,218 
Share-based compensation   521,006    389,343 
Amortization of right-of-use assets   226,061    88,620 
Loss on disposal of assets   11,355    - 
Interest income received on short-term investments   46    159 
Unrealized gain on derivative warrants liability   -    (242,628)
Unrealized foreign exchange loss   312    (571)
Payments on lease obligations   (232,633)   (66,537)
Finance expense   -    360,350 
Changes in non-cash working capital:          
Inventories   (933,260)   - 
Prepaids and other assets   (323,653)   (1,192,936)
Other non-current assets   6,580    (14,161)
Accounts receivable   (22,535)   (18,183)
Accounts payable and accrued liabilities   (195,125)   (235,892)
Deferred revenue   3,760    - 
Total cash used in operating activities   (11,536,511)   (7,784,554)
           
Investing Activities          
Cash acquired from acqusition of BayMedica   91,566    - 
Purchase of property and equipment   (39,108)   - 
Total cash provided by investing activities   52,458    - 
           
Financing Activities          
Shares issued for cash   12,000,001    12,472,500 
Share issuance costs   (1,294,247)   (1,534,602)
Repayment of debt   (261,514)   - 
Settlement of debt upon acquisition of subsidiary   (425,000)   - 
Total cash provided by financing activities   10,019,240    10,937,898 
Effects of foreign exchange on cash and cash equivalents   -    494,960 
Increase (decrease) in cash during the period   (1,464,813)   3,648,304 
Cash and cash equivalents beginning of the period   7,363,126    5,805,809 
Cash and cash equivalents end of the period   5,898,313    9,454,113 

 

7

 

 

About InMed: InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica, LLC, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is also a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com and www.baymedica.com.

 

Investor Contact:

 

Colin Clancy

Senior Director, Investor Relations

T: +1.604.416.0999

E: cclancy@inmedpharma.com

 

Cautionary Note Regarding Forward-Looking Information:

 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: expanding rare cannabinoid portfolio; strengthening IP with publication of a patent application for novel cannabinoid analogs; commencing sales of the rare cannabinoids CBDV and CBT as raw ingredients for the health and wellness industry; commercial scale production of delta-9 dominant tetrahydrocannabivarin (“THCV”) in anticipation of commencing B2B sales; CBDV and THCV being highly anticipated; several additional high-value rare cannabinoids in various stages of development and commercial manufacturing scale-up; establishing a reliable supply of rare cannabinoids at commercial scale for manufacturers and consumer brands to deliver improved and differentiated products; evaluating potential partners and co-development collaborations for novel product development; supplying the rare cannabinoid THCV for incorporation into Trokie’s proprietary product formulation that will then be evaluated in Radicle Science’s “Radicle Energy” study on energy, focus/attention, appetite and weight/body mass index (“BMI”); enrollment and patient treatment of the Company’s Phase 2 clinical trial, 755-201-EB, of INM-755 (cannabinol) cream in the treatment of EB;  the 755-201-EB study including 13 sites across 8 countries with enrollment and patient treatment being completed during the calendar year 2022; the 755-201-EB study enrolling up to 20 patients to study the safety and preliminary efficacy of INM-755 (cannabinol) cream; having Company recently completed a pre-Investigational New Drug (“pIND”) application discussion with the U.S. Food and Drug Administration (“FDA”) regarding manufacturing, preclinical studies and early clinical development plans for INM-088, a cannabinol (“CBN”) formulation in development for glaucoma; gaining alignment with FDA on the design of the initial Phase 1-2 clinical trial to gather preliminary data on the safety and efficacy of INM-088 treatment; the FDA providing guidance for the development program based on a summary of the available preclinical data, clinical safety data for CBN from the INM-755 program, study designs for additional IND-enabling preclinical studies, and Chemistry Manufacturing and Controls (“CMC”) information; expecting to file regulatory applications in the first half of the calendar year 2023, to initiate a human clinical trial; the publication of a patent application in North America for several cannabinoid analogs covering broad claims directed to their molecular structure, uses and methods of manufacturing; technology that allows for the creation of libraries of new chemical entities (“NCEs”), which the Company will screen in several in vitro and in vivo models to select therapeutic candidates for advancement; the initiation of a research collaboration agreement with the Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila (Italy) in the laboratory of Dr. Mauro Maccarrone to screen the Company’s novel cannabinoid analogs to investigate pharmacological properties and potential therapeutic uses; the Company anticipates revenue growth in the coming quarters with the commercialization of CBDV and THCV as well as additional planned launches; being a global leader in the research, development, manufacturing and development of rare cannabinoids; and delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.

 

With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

 

Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

 

 

8

 

 

 EX-101.SCH 3 inm-20220512.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 inm-20220512_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 inm-20220512_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^D+!02Q M ZDTM)_PD^N2:?O<:79?\?&QL>;*>B9] .M5%7$W8Z'[=9_\ /U!_W\%' MVZS_ .?J#_OX*S1X3T #']E6V/\ =I3X3T#&/[*MO^^:/<\Q>\;"LKJ&5@RG MH0<@U%)=6\3;9)XD;T9P#7$:M++X)NDAT\L;74SY-O$S9$$YZ$9_AK%+6&W-WHL(L]0@^>(Q$@.1_"P[@TDHOJ%Y+H M=/15#1M3CU?2X;M!M+##IW1QP0?QJ_4M6=F4G?4****0PHHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** ,GQ#JCZ;IW[@;[RX80VZ>KGO^'6IM%TQ- M(TN*U!WO]Z5SU=SR3^=9GBI)(#IVKJA=-/GWRH.NQA@G\.M=!%*DT22QL&1P M&5AT(-6](JQ"^)CZ0D $DX ZFD=UCC9W8*BC))["N2@L)_%PGOKJ[N8+!]T= MI!$Q3WKFE&-]7L-NVB/,_B-X[5=?MPD?FP[MH7&2D(."X]&)Y'L*]:\' MZXNM:*C-('GA 5V_O@C*M^(KS*>QETMDL!;K)+"_D/YA).[L&0@?*,%L>F>E=-2$>35Z=#"$WS:+4]'HK#\.ZC<3K<: M?J# ZA9-LD/3S%_AN9\ M2G^TK_3]$@YE:9;B5A_RSC4]?Q/%=-52V39,=V@HHHJ"PHHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** &R1I+&TE=!##'!"D,2A8T4*JCL!7!6VDZI:>,;NWFU^= M)+N%7AF,2GS O5?J*W_[#UC_ *&2X_[\I5RBDDKD1;NW8Y[Q^JIJEFUKN\Z1 M<7VP9*VX/W_8CM7=V4<$5E!':A?LZH!'MZ;<<5G:9X>M[!;EYI9+RXNAMFFG M.2P]/8>U4HO#%W9*8M.URZM[;.4A*JX3V!/:AM22C?8$FFW;<7Q'#)I]U;^( M;9"7MODN47_EI">OXCK6Q&;*;RYM7O5Q>WYWD'_ )9Q_P *?E6_2#':EK)N[N:)65@HHHI#"BBDR/6@ M!:*** "BBDR,XR,T +1110 4444 %%%% !14%[:+4K M$1S2(#$V0C$=Z[G2-*AT?3TM8BSG)9Y&^\['J37!?$W_ )"5A_UQ;^=:T6G4 M26QE534&WN;'PWEDET:[,DCN1<8RS$_PBNTKSSP5>MIW@W5KU$#M#(SA3T)" MBL>X^(6NRDF-H(1Z+'G^=.5&4YRY11JQA!7/6Z*\;'CCQ I#?;0?8QC%=3X: M\>M?7<=EJB(DDAVQS)P"?0CM4RP\XJY4:\6['<2N(X7Z;XPU;2? M$\>LPWEP[1W!E,3RL5923E2,XY!(KZR\17'V7PSJMQ_SSM)7_)#7RCX2\*3> M*K;6A;9^T6-G]IB4?QG=]W\1G\:BG:SN7/R/K32-4MM:TFUU*S??;W,8D0^Q M[?4=*NUX?\ _%6^*Z\,7+\IFXM<^G\:_GS^)KW"HDK.Q2=U&K MW5[C!$"?(A/WW/"K^)KY=\/>)=5N?'VF7]U?W#O-J,;R+YK;3N?!&,XQS7;_ M !S\2R:KX@M/#%BQD2V(:5$_CF;A5_ '\S7$>)/#[>"O%^G63N6EB2VN)#VW MD@MCV!%:P5EZD2>I]=T5!-=PVUD]W<2K%!''YCNQP%4#))KPOQ)\,R22^ZIV%9*+>Q;:1[W17S=/\ $3XH^']MUJMO*ENQ_P"7JS 0 M^V1TKUGX=_$:S\#M M%?4=18D9VQ0I]Z5_0?X]J\,NOC'XXUZ^>/0[184_AAM[?SF ]R?_ *U"BV-R M2/H'7?\ D7M2_P"O27_T U\]? 7_ )*!-_UXR?\ H2T^3XK^.=+MY[3Q#I_F M07$31?O[^K_^@"L3P;&DOBNR21%=3NRK#(Z&MSPW_P D\U[ZO_Z *Q?!/_(W M6/\ P+_T$UT])_UT.?K ];GTVQN8&AFM(7C88(*"O$M6M/[+UJZM4)Q!*0A[ MX!XKWBO$_%O_ "-6I?\ 77^E8X5OF:-,0E9,[WQC>EOA5J=V3AI-.)/U90/Z MUYA^SO%G4]=DQT@A7]6KNO'DWD_!"[;ULH5_,H*Y/]G>+]QKTV/XXD_0FLMH MLUW:.2\9V,_PU^*T6J6*E;5Y1=P ="A/[Q/YC\:^@-4\46.G>#IO$?F!K5;; MSXSG[^1\H_$D"N6^,WAC^W_!4EW!'NO--)G3 Y*?QC\N?PKP:Z\:7MW\/K+P MH=QBM[@R;\YWIU1/P)/Z4)%O!-E:NFVZG'VBY/?>W;\!@ M?A7D_P"T)%M\3:5)_?LV'Y-_]>A.\Q-6B=%\9O$P@D*G5 C2D'K&J MAB/H213?@I9:!H_AUM8O;VQ34[MV \V90T<8. ">,\FN6^*^^?P;X%O.J-8 MA"?]K8A_I1X,^#EKXO\ "]KK*ZX\+3;E>(0!MC D8SGZ?G19:EILUO,I1XWN$((/XU\X^"IQX:^,EK;6]6R'C8D#GOV_ M*NX_X9U@_P"AAD_\!A_C5[1_@-%I.M6.HC7Y)/LLZS;/( W;3G&/QI<;$Q6,:0QIV,CX)/UY _"O=_!OA:R\)^';6PM85678&GEQ\ MTCDR01W M9E^)[.VO?#.I174$F5C:YINA7CQ3:QY *@JC2R[./SK2E-0G=D5(N4;(XOPW M_P D\U[ZO_Z *QO!/_(VV/\ P+_T$UZ0EIX?TW3!9Q^4MGJ$HA4*Y82NPZ C MV%2V7A71M/NTNK6S6.9,[6#'BMO;QM+S,O9.\?(V:\3\7?\ (U:E_P!=?Z5[ M96+=^$]$OKJ2YN+)7FD.6;<>3^=9T:BA*[+JPDZUHR:1J%H)K%-N(BQ ^7ITIOA_POH_ MA:VEM]'LUM8I7\QU5B:AR5FBU'5&K(BRQM&ZAD8%6![@UX]IOP(@L?% M<.I2:FLNGPW/G+:^5R0#E5)SVX_*O8Z*E-K8;285X%^T1'_Q,]"D_P"F,R_J MM>^U@^(/".@>*GA_MBR2Z:W!\L%R"N[KT/M3B[.X25U8X&3PJWC?X%:-!;8- M];VZRVV?XF7(*_B,C\J\[^'WQ%N_AY=W.E:I9326329D@^[)!)T) /KW%?1^ MAV>F:?H\%GH_EBQ@W)&(WW!<,'/%!WZKID4LP&!,ORR#_@0_ MK34EL]A./5',+\\!_N&W.?YUI^#?B5I?C?5KVRT^WN(A;1K('FP# M("<' [8X_.L&+X,^ Y-2FLT-ZUQ"BO)%]I/RALX/3O@UVGAWP7X?\*EVT?3H M[>5UVO+DL[#T)-#Y;: N;J>;_&_P+6\$MY++- \: 0$'?#,AETC2X;:8KM,H MR7(],FG>*5D*S;U-^BBBLRPHHHH **** "BBB@ K@_%<^FV_CS17U6V^T6_V M*X 3[.9OFW)@[0#[\UWE9<^C^=XEL]8\\@VUO+!Y6W[V\J-; MU)[];XP3B&%8?W0<(\4AD5B"?F'.,?K3NF*QS;>-]1AMM5MK?4+:_EA%LT%V M;8QX$LFPAD[D=1CKFMB[N/$D&O:;H:ZS 7NHIIWNC9C(";0%"YQ_$>:6Y\&: MAJLUU<:IJT+SS)!&OD6I156*7S.A8Y).16]V-OZT70:G)#6/%G]CZQJ37]@6T::6)X%MCBY$8#$EMV5)![=#4GB7Q?)IP MDO+/7;5'B@2;^S7MBY;(SM9Q]TD=*W_^$9']DZ[8?:C_ ,366:0OL_U7F*%Q MC/.,5D3>"M1BM=2L=/UB&*QU(?Z0LMIO=6*!&*L&'!"C@YQ1=!J6+;4=;\1Z MA>G3+V#3[&SE$ WP>:\K[0S9R1@#=CCFN=G^(%X\-YJ=OJ5FBVTSI%I;6[,\ MZ(VUB7'1C@D <=*Z=?#6IZ=?3SZ)JT5O%=;6N(;BV\T>8%"EUPPP2 ,CD46? MAS5](D>'2M8ABT^28S&&>UWM&6.7"-N'!.2 0<9HT#4?I^O7=YI?B"Z8(&L9 MI5@&W&%6-6&[WR:P_#LNK:OXDNKZ&_BM_-L;&6X0P;PY*L3CGY>]:]YX7U,7 M.J'2M6AMK74R6N(9[;S-CE=K,A##J .#WHMO"NH:5>0S:3JT<2FUAM;A9[;S M-XBR RX88)!([BC0#*TK6]3U)[;1]*^R6$K&YN)YU@!"(L[(H5. 68\DGWJS MK^L7NC11PR>*;.*_B@:1HFLMWG')P6 )*#'%6(_!MS8?9;G3-4$&H6YG!ED@ MW)+'+(9"C+GL3P0:3_A%]=AO+R]M];M!:IV/A*]T@H^F:JD<@T^*S8S6^\%H_NOC<,<$@BKFB:!7<:1,+>#RD"J202,DEOF/)/H*'8$=!1114C"BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** )** "BBB@#__9 end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
May 12, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 12, 2022
Entity File Number 001-39685
Entity Registrant Name INMED PHARMACEUTICALS INC.
Entity Central Index Key 0001728328
Entity Tax Identification Number 98-1428279
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One Suite 310 - 815 W. Hastings Street
Entity Address, City or Town Vancouver, B.C.
Entity Address, Country CA
Entity Address, Postal Zip Code V6C 1B4
City Area Code (604)
Local Phone Number 669-7207
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol INM
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 ea160171-8k_inmedphar_htm.xml IDEA: XBRL DOCUMENT 0001728328 2022-05-12 2022-05-12 iso4217:USD shares iso4217:USD shares 0001728328 false A1 8-K 2022-05-12 INMED PHARMACEUTICALS INC. 001-39685 98-1428279 Suite 310 - 815 W. Hastings Street Vancouver, B.C. CA V6C 1B4 (604) 669-7207 false false false false Common Shares, no par value INM NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inmedpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea160171-8k_inmedphar.htm ea160171ex99-1_inmedphar.htm inm-20220512.xsd inm-20220512_lab.xml inm-20220512_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea160171-8k_inmedphar.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ea160171-8k_inmedphar.htm" ] }, "labelLink": { "local": [ "inm-20220512_lab.xml" ] }, "presentationLink": { "local": [ "inm-20220512_pre.xml" ] }, "schema": { "local": [ "inm-20220512.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "INM", "nsuri": "http://inmedpharma.com/20220512", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea160171-8k_inmedphar.htm", "contextRef": "From2022-05-12to2022-05-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://inmedpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea160171-8k_inmedphar.htm", "contextRef": "From2022-05-12to2022-05-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 16 0001213900-22-027887-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-027887-xbrl.zip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end